The company is planning to establish a drug production facility in Europe by 2008, with the UK seen as one of its priority countries for investment.
Eisai said in a statement to PRWeek: 'At that time  we would look for appropriate agency support to announce further details of our investment.'
The company recently brought in Andrew Day as its first European PR director (PRWeek, 12 August). Day moved from a role as
interim product comms manager at Lilly.
A decision on the location of Eisai's European production facility is believed to be imminent, with Eisai seeing the UK as 'one of the more attractive options'.
Eisai brands include Aricept (for Alzheimer's disease), Pariet (acid-related disorders) and Zonegran (migraines).
Eisai said negotiations were ongoing with various parties over the location of its planned production site and that it was 'unable' to comment further on company strategy.